Weight gain on dolutegravir: Association is not the same as causation.
作者信息
Maartens Gary, Sinxadi Phumla, Venter W D Francois
机构信息
Division of Clinical Pharmacology, Department of Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
Ezintsha, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
出版信息
South Afr J HIV Med. 2023 May 15;24(1):1500. doi: 10.4102/sajhivmed.v24i1.1500. eCollection 2023.
Abstract
摘要
相似文献
1
Weight gain on dolutegravir: Association is not the same as causation.多替拉韦导致体重增加：关联并不等同于因果关系。
South Afr J HIV Med. 2023 May 15;24(1):1500. doi: 10.4102/sajhivmed.v24i1.1500. eCollection 2023.
2
Could a Dolutegravir-Based Antiretroviral Therapy Lead to Clinical Obesity? A Retrospective Cohort Study Conducted at Hawassa University Comprehensive Specialized Hospital in Hawassa, Sidama, Ethiopia.基于多替拉韦的抗逆转录病毒疗法会导致临床肥胖吗？在埃塞俄比亚锡达马州哈瓦萨市的哈瓦萨大学综合专科医院进行的一项回顾性队列研究。
AIDS Res Treat. 2022 May 13;2022:2965325. doi: 10.1155/2022/2965325. eCollection 2022.
3
Concentration-response relationships of dolutegravir and efavirenz with weight change after starting antiretroviral therapy.开始抗逆转录病毒治疗后，多替拉韦和依非韦伦与体重变化的浓度-反应关系。
Br J Clin Pharmacol. 2022 Mar;88(3):883-893. doi: 10.1111/bcp.15177. Epub 2022 Jan 26.
4
Greater Weight Gain in Treatment-naive Persons Starting Dolutegravir-based Antiretroviral Therapy.初治人群开始使用多替拉韦为基础的抗逆转录病毒治疗时体重增加较多。
Clin Infect Dis. 2020 Mar 17;70(7):1267-1274. doi: 10.1093/cid/ciz407.
5
Pro-Inflammatory Interactions of Dolutegravir with Human Neutrophils in an In Vitro Study.在一项体外研究中，地拉韦啶与人类中性粒细胞的促炎相互作用。
Molecules. 2022 Dec 19;27(24):9057. doi: 10.3390/molecules27249057.
6
Dolutegravir-Based or Low-Dose Efavirenz-Based Regimen for the Treatment of HIV-1.基于多替拉韦的或基于低剂量依非韦伦的方案治疗人类免疫缺陷病毒 1 型。
N Engl J Med. 2019 Aug 29;381(9):816-826. doi: 10.1056/NEJMoa1904340. Epub 2019 Jul 24.
7
Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon.多替拉韦钠联合低剂量依非韦伦方案与整合酶抑制剂联合依非韦伦方案初治人类免疫缺陷病毒 1 型感染的疗效比较（NAMSAL）：喀麦隆两项多中心、随机、开放标签、平行对照、Ⅲ期非劣效临床试验第 96 周结果
Lancet HIV. 2020 Oct;7(10):e677-e687. doi: 10.1016/S2352-3018(20)30238-1.
8
Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials.固定剂量复方比克替拉韦、恩曲他滨和丙酚替诺福韦艾拉酚胺与含多替拉韦方案治疗初治人类免疫缺陷病毒 1 型感染：两项随机、双盲、多中心、Ⅲ期、非劣效性临床试验的 144 周结果。
Lancet HIV. 2020 Jun;7(6):e389-e400. doi: 10.1016/S2352-3018(20)30099-0.
9
"It's only fatness, it doesn't kill": a qualitative study on perceptions of weight gain from use of dolutegravir-based regimens in women living with HIV in Uganda.“只是胖了而已，又死不了”：乌干达 HIV 感染者使用多替拉韦方案后对体重增加的定性研究
BMC Womens Health. 2022 Jun 21;22(1):246. doi: 10.1186/s12905-022-01814-x.
10
Weight gain during the dolutegravir transition in the African Cohort Study.在非洲队列研究中，在换用多替拉韦期间体重增加。
J Int AIDS Soc. 2022 Apr;25(4):e25899. doi: 10.1002/jia2.25899.
引用本文的文献
1
Effect of weight gain on blood pressure in Ugandan persons with HIV on dolutegravir/lamivudine/ tenofovir disoproxil fumarate over 48 weeks.乌干达接受多替拉韦/拉米夫定/替诺福韦酯治疗的HIV感染者体重增加对48周血压的影响。
PLoS One. 2025 Jun 11;20(6):e0325020. doi: 10.1371/journal.pone.0325020. eCollection 2025.
2
Long-term metabolic changes with bictegravir/emtricitabine/tenofovir alafenamide or dolutegravir-containing regimens for HIV.使用比克替拉韦/恩曲他滨/替诺福韦艾拉酚胺或含多替拉韦的方案治疗HIV的长期代谢变化
AIDS Res Ther. 2025 Apr 7;22(1):45. doi: 10.1186/s12981-025-00732-w.
3
Impact of switching to a dolutegravir-based regimen on body weight changes: insights from West African adult HIV cohorts.基于多替拉韦方案转换对体重变化的影响：来自西非成人 HIV 队列的研究结果。
J Int AIDS Soc. 2024 Dec;27(12):e26371. doi: 10.1002/jia2.26371.
4
DORA: 48-week weight and metabolic changes in Black women with HIV, in a phase IIIb switch study from dolutegravir- or efavirenz- to doravirine-based first-line antiretroviral therapy.多拉：在一项从多替拉韦或依非韦伦转换为基于多拉韦林的一线抗逆转录病毒治疗的IIIb期转换研究中，感染艾滋病毒的黑人女性48周的体重和代谢变化。
HIV Med. 2025 Jan;26(1):81-96. doi: 10.1111/hiv.13711. Epub 2024 Sep 17.
5
Assessment of weight gain in adult patients living with HIV receiving first-line dolutegravir-based or efavirenz-based ART regimens in routine care clinics in Tshwane district, South Africa: An observational study.南非茨瓦尼地区常规护理诊所中接受一线多替拉韦或依非韦伦为基础的抗逆转录病毒治疗方案的艾滋病毒感染者成年患者体重增加评估：一项观察性研究。
HIV Med. 2024 Jul;25(7):826-839. doi: 10.1111/hiv.13638. Epub 2024 Mar 22.
本文引用的文献
1
Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial.多替拉韦加拉米夫定与恩曲他滨和丙酚替诺福韦艾拉酚胺或富马酸替诺福韦二吡呋酯对比依非韦伦、恩曲他滨和富马酸替诺福韦二吡呋酯，用于治疗人类免疫缺陷病毒 1 型感染的初始治疗（ADVANCE）：一项随机、3 期、非劣效性试验的第 96 周结果。
Lancet HIV. 2020 Oct;7(10):e666-e676. doi: 10.1016/S2352-3018(20)30241-1.
2
CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz.CYP2B6 基因型与多替拉韦和依非韦伦所致体重增加的差异。
Clin Infect Dis. 2021 Dec 6;73(11):e3902-e3909. doi: 10.1093/cid/ciaa1073.
3
Efavirenz Pharmacogenetics and Weight Gain Following Switch to Integrase Inhibitor-Containing Regimens.依非韦伦的药物遗传学与换用含整合酶抑制剂方案后的体重增加。
Clin Infect Dis. 2021 Oct 5;73(7):e2153-e2163. doi: 10.1093/cid/ciaa1219.
4
Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada.在美国和加拿大的一个大型观察性队列中，与非核苷类逆转录酶抑制剂或蛋白酶抑制剂相比，初治 HIV 感染者开始使用整合酶抑制剂后体重增加。
J Int AIDS Soc. 2020 Apr;23(4):e25484. doi: 10.1002/jia2.25484.
5
Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials.抗逆转录病毒治疗起始后体重增加：随机对照临床试验中的危险因素。
Clin Infect Dis. 2020 Sep 12;71(6):1379-1389. doi: 10.1093/cid/ciz999.
6
The obesity transition: stages of the global epidemic.肥胖流行的转变：全球流行阶段。
Lancet Diabetes Endocrinol. 2019 Mar;7(3):231-240. doi: 10.1016/S2213-8587(19)30026-9. Epub 2019 Jan 28.
7
Key toxicity issues with the WHO-recommended first-line antiretroviral therapy regimen.世界卫生组织推荐的一线抗逆转录病毒治疗方案的关键毒性问题。
Expert Rev Clin Pharmacol. 2016 Nov;9(11):1493-1503. doi: 10.1080/17512433.2016.1221760. Epub 2016 Aug 22.
8
Impact of elvitegravir on human adipocytes: Alterations in differentiation, gene expression and release of adipokines and cytokines.埃替格韦对人脂肪细胞的影响：脂肪生成、基因表达以及脂肪因子和细胞因子释放的改变。
Antiviral Res. 2016 Aug;132:59-65. doi: 10.1016/j.antiviral.2016.05.013. Epub 2016 May 20.
9
Pharmacogenetics of plasma efavirenz exposure in HIV-infected adults and children in South Africa.南非成人和儿童HIV感染者血浆依法韦仑暴露的药物遗传学
Br J Clin Pharmacol. 2015 Jul;80(1):146-56. doi: 10.1111/bcp.12590. Epub 2015 May 28.
Zotero 插件